Clincosm LogoSign in Get a demo

Development of the Oncology Opportunity Cost Assessment Tool

Sponsor
Thomas Jefferson University (Other)
Overall Status
Completed
CT.gov ID
NCT04694911
Collaborator
(none)
40
Enrollment
1
Location
20.3
Actual Duration (Months)
2
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study develops and tests an instrument to measure opportunity costs called the Oncology Opportunity Cost Assessment Tool (OOCAT) in cancer patients. Patients experience significant costs, both direct financial as well as indirect costs, associated with seeking cancer treatment. While the direct financial impact of care on patients is receiving increased attention, other important consequences, such as opportunity cost, remain largely unmeasured. Opportunity cost is an economics term that refers to the loss of potential benefits from other options when one option is chosen - if resources are used for one purpose, they are no longer available for the next best option. The information and knowledge gained from this study may help researchers develop the OOCAT, which may allow them to understand the opportunity cost of treatment for each patient. The OOCAT may then be used to determine not just the best medications for patients, but also the best comprehensive treatment plan that will allow them to get the right treatment in the right place at the right time.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Focus Group
  • Other: Interview
  • Other: Research or Clinical Assessment Tool

Study Design

Study Type:
Observational
Actual Enrollment :
40 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Development of the Oncology Opportunity Cost Assessment Tool (OOCAT)
Actual Study Start Date :
Nov 21, 2019
Actual Primary Completion Date :
May 11, 2021
Actual Study Completion Date :
Jul 31, 2021

Arms and Interventions

Arm Intervention/Treatment
Health Services Research (focus group, interview, OOCAT)

FOCUS GROUP: Patients participate in focus group session over 60-90 minutes. COGNITIVE INTERVIEW: Patients complete cognitive interview on the clarity, interpretability, and ease of use of the OOCAT. FEASIBILITY TESTING: Patients receive OOCAT at the point of care, online, or via telephone, per patients' preference.

Behavioral: Focus Group
Participate in focus group

Other: Interview
Complete cognitive interview

Other: Research or Clinical Assessment Tool
Receive OOCAT
Other Names:
  • Clinical Assessment Tool, Clinical Assessment Tool, Clinical or Research Assessment Tool

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Patient-level opportunity costs associated with oncology care [1 Day of Interview]

      Patient-identified themes that contribute to opportunity cost will be generated via patient focus groups

    2. Development of the Oncology Opportunity Cost Assessment Tool (OOCAT) [1 Day of Interview]

      Will organize themes into domains and will generate items representing each of the themes for inclusion in an instrument designed to measure patient opportunity cost of seeking care. Will perform cognitive interviews with a random sampling of patients from the cancer center to test initial instrument items to ensure content validity and clarity of each item.

    3. Implementation of OOCAT [1 Day of OOCAT administration]

      Will test the instrument as developed with patients receiving oncology care across the Jefferson Health System to gather preliminary data informing the reliability of the scale to measure opportunity cost of seeking care.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Male
    Inclusion Criteria:

    • Treated for cancer at one of the 3 participating sites (Jefferson Center City, Jefferson Methodist Hospital, Jefferson Abington)

    • English speaking

    • Able to attend and participate in a focus group

    Exclusion Criteria:

    • Treated at a Jefferson site other than the ones mentioned

    • Non-English Speaking

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Sidney Kimmel Cancer Center at Thomas Jefferson University Philadelphia Pennsylvania United States 19107

    Sponsors and Collaborators

    • Thomas Jefferson University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Thomas Jefferson University
    ClinicalTrials.gov Identifier:
    NCT04694911
    Other Study ID Numbers:
    • 19G.854
    First Posted:
    Jan 5, 2021
    Last Update Posted:
    Aug 16, 2022
    Last Verified:
    Aug 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Neoplasms

    Study Results

    No Results Posted as of Aug 16, 2022